Frontiers in immunology · 2025
Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Favalli Andrea, Patelli Giorgio, Gruarin Paola, Gobbini Andrea, Pesce Elisa, Mariano Sara, Bombaci Mauro, Vincenti Francesca, Donnici Lorena, Marchese Silvia, Piscazzi Daniele, Amatu Alessio, Tosi Federica, Ghezzi Silvia, Pani Arianna, Principato Silvia, Lombardi Andrea, Bandera Alessandra, Abrignani Sergio, Siena Salvatore, Sartore-Bianchi Andrea, Grifantini Renata
Аннотация
INTRODUCTION: Despite SARS-CoV-2 pandemic has subsided, vaccine response profiling in patients with cancer remains critical.
METHODS: We longitudinally assessed humoral and cellular immunity in adults with solid tumours treated with chemotherapy (ChT) or non-ChT regimens after two mRNA vaccine doses plus booster, compared with vaccinated cancer-free controls, naturally infected (convalescent) subjects including both patients with cancer and cancer-free individuals, and unvaccinated/uninfected individuals with or without cancer as a baseline reference.
RESULTS: Anti-Spike IgG titres matched cancer-free controls, but anti-RBD titres and neutralising activity were consistently lower in cancer post-vaccination, most markedly with ChT, and declined faster over 4-6 months. Boosters restored IgG, yet gains were smaller in ChT recipients. Cellular analyses revealed sustained and booster-enhanced Spike-specific B cells in all groups; however, ChT exposure was associated with reduced CD27 expression on these cells, suggesting impaired activation and memory maturation.
DISCUSSION: These findings support tailored immune monitoring and vaccination strategies in oncology and identify CD27 downregulation as a novel B-cell dysfunction detected by high-dimensional immunophenotyping.
METHODS: We longitudinally assessed humoral and cellular immunity in adults with solid tumours treated with chemotherapy (ChT) or non-ChT regimens after two mRNA vaccine doses plus booster, compared with vaccinated cancer-free controls, naturally infected (convalescent) subjects including both patients with cancer and cancer-free individuals, and unvaccinated/uninfected individuals with or without cancer as a baseline reference.
RESULTS: Anti-Spike IgG titres matched cancer-free controls, but anti-RBD titres and neutralising activity were consistently lower in cancer post-vaccination, most markedly with ChT, and declined faster over 4-6 months. Boosters restored IgG, yet gains were smaller in ChT recipients. Cellular analyses revealed sustained and booster-enhanced Spike-specific B cells in all groups; however, ChT exposure was associated with reduced CD27 expression on these cells, suggesting impaired activation and memory maturation.
DISCUSSION: These findings support tailored immune monitoring and vaccination strategies in oncology and identify CD27 downregulation as a novel B-cell dysfunction detected by high-dimensional immunophenotyping.
Предметные рубрики MeSH
HumansNeoplasmsCOVID-19Middle AgedSARS-CoV-2FemaleMaleCOVID-19 VaccinesImmunity, HumoralImmunity, CellularAgedAntibodies, ViralAdultVaccinationSpike Glycoprotein, CoronavirusB-LymphocytesTumor Necrosis Factor Receptor Superfamily, Member 7Immunoglobulin GAntineoplastic AgentsImmunization, SecondaryAntibodies, Neutralizing